NK 042
Alternative Names: NK-042Latest Information Update: 22 May 2024
At a glance
- Originator NK CellTech
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 May 2024 Anhui Provincial Hospital plans a phase I trial for Gynaecological cancer in China (Intraperitoneal, Infusion) in May 2024 (NCT06415500)
- 02 Feb 2024 Preclinical trials in Cancer in China (Intraperitoneal, Infusion), prior to February 2024 (NK CellTech pipeline, February 2024).